RecruitingPHASE1, PHASE2NCT07391215

5G-PEARL: Paxalisib in Malignant Brain Tumours

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Cancer Research, United Kingdom
Principal Investigator
Juanita Lopez, MD, PhD
National Health Service, United Kingdom
Intervention
Paxalisib(drug)
Enrollment
64 target
Eligibility
16 years · All sexes
Timeline
20262029

Study locations (1)

Collaborators

Minderoo Foundation · Kazia Therapeutics Limited · Royal Marsden NHS Foundation Trust · Cambridge University Hospitals NHS Foundation Trust · Cancer Research UK

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07391215 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials